Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | MET | P08581 | 9/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742664 | 0.90 | MAPT (0.53) | MAPTMETKDRLMNAPOLB | |
| SCHEMBL1741245 | 0.80 | POLB (0.52) | MAPTMETKDRLMNAPOLB | |
| SCHEMBL1742657 | 0.79 | MAPT (0.49) | MAPTMETKDRLMNAPOLB | |
| SCHEMBL1742107 | 0.77 | MET (0.52) | MAPTMETKDRLMNAAXL | |
| SCHEMBL1742101 | 0.77 | LMNA (0.47) | MAPTMETKDRLMNAPOLB | |
| SCHEMBL1742629 | 0.75 | MET (0.43) | MAPTMETKDRLMNAPOLB | |
| SCHEMBL1742630 | 0.74 | MET (0.47) | MAPTMETKDRLMNAAXL | |
| SCHEMBL15529231 | 0.73 | MAPT (0.50) | MAPTLMNAPOLBNPC1RAB9A | |
| SCHEMBL1741220 | 0.71 | CA12 (0.45) | MAPTMETKDRLMNAKMT2A | |
| SCHEMBL1742632 | 0.70 | MET (0.45) | METKDRPOLBAXLUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563579-B2 | α-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2013-10-22 | — | — | US | claimed |
| EP-2387575-B1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-09-04 | — | — | EP | claimed |
| EP-2387575-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2011-11-23 | — | — | EP | claimed |
| US-D647030-S1 | Automobile tire tread | THE YOKOHAMA RUBBER CO., LTD (JP) | 2011-10-18 | — | — | US | claimed |
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ALPHARMAGEN LLC | 2010-07-29 | — | — | US | claimed |
| WO-2010083444-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL, LLC (US) | 2010-07-22 | — | — | WO | claimed |
| US-8975407-B2 | α7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140194462-A1 | Alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ANVYL LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8563579-B2 | α-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2387575-B1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2387575-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-D647030-S1 | Automobile tire tread | THE YOKOHAMA RUBBER CO., LTD (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ALPHARMAGEN LLC | 2010-07-29 | — | — | US | disclosed |
| WO-2010083444-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL, LLC (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | CHRNA7, CHRNA1, CHRNG | MAPT 2116/4885MET 4323/4885KDR 4098/4885 |
| US-20140194462-A1 | Alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | CHRNA7, CHRNA1, CHRNG | MAPT 2116/4885MET 4323/4885KDR 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.